Unlock instant, AI-driven research and patent intelligence for your innovation.

Teneligliptin key intermediate preparation method

A technology for tiagliptin and intermediates, which is applied in the field of preparation of key intermediates of tiagliptin, and can solve the problems of unsuitability for industrial scale-up production, low total yield, and many steps

Inactive Publication Date: 2016-02-17
湖南华腾制药有限公司
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Patent CN102675321A has announced the preparation method (Scheme3) of another kind of 1-(3-methyl-1-phenyl-1H-pyrazol-5-yl))piperazine, and this method steps is many, and total yield is low, not Suitable for industrial scale-up production

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Teneligliptin key intermediate preparation method
  • Teneligliptin key intermediate preparation method
  • Teneligliptin key intermediate preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] (1) Preparation of compound IIIa:

[0020]

[0021] Compound IV (160 g, 1 mol) was added to 900 ml of tetrahydrofuran, sodium tert-butoxide (115.2 g, 1.2 mol) was slowly added in batches, stirred for 20 minutes, and iodobenzene (243.6 g, 1.2 mol) was added dropwise. The mixture was heated to reflux and stirred for 4 hours, then stirred at room temperature overnight, TLC showed that the reaction was complete, the reaction solution was slowly poured into ice water, ethyl acetate was added, the organic phase was separated, the aqueous phase was extracted again with ethyl acetate, the organic phases were combined, and dried , and concentrated to obtain 205.3 g of compound IIIa with a yield of 87%.

[0022] (2) Preparation of Compound IIa:

[0023]

[0024] Compound N-Boc-piperazine (149.1g, 0.8mol) was added to xylene (1500ml), then sodium hydride (32g, 0.8mol) was added, stirred for 30 minutes, and compound IIIa (188.8g, 0.8mol) was slowly added , the mixture was h...

Embodiment 2

[0029] (1) Preparation of compound IIIb:

[0030]

[0031] Compound IV (160 g, 1 mol) was added to 850 ml of acetonitrile, potassium tert-butoxide (134.6 g, 1.2 mol) was slowly added in batches, stirred for 30 minutes, and iodobenzene (243.6 g, 1.2 mol) was added dropwise. The mixture was heated to reflux and stirred for 4 hours, then stirred at room temperature overnight, TLC showed that the reaction was complete, the reaction solution was slowly poured into ice water, ethyl acetate was added, the organic phase was separated, the aqueous phase was extracted again with ethyl acetate, the organic phases were combined, and dried , and concentrated to obtain 200.5 g of compound IIIb with a yield of 85%.

[0032] (2) Preparation of Compound IIb:

[0033]

[0034] The compound N-Boc-piperazine (149.1g, 0.8mol) was added to N,N-dimethylformamide (1550ml), then sodium tert-butoxide (76.8g, 0.8mol), stirred for 40 minutes, slowly Add compound IIIb (188.8g, 0.8mol), heat the mi...

Embodiment 3

[0039] (1) Preparation of compound IIIc:

[0040]

[0041] Compound IV (160 g, 1 mol) was added to 920 ml of 1,4-dioxane, sodium hydride (48 g, 1.2 mol) was slowly added in batches, stirred for 25 minutes, and iodobenzene (243.6 g, 1.2 mol) was added dropwise. The mixture was heated to reflux and stirred for 4.5 hours, then stirred at room temperature overnight, TLC showed that the reaction was complete, the reaction solution was slowly poured into ice water, ethyl acetate was added, the organic phase was separated, the aqueous phase was extracted with ethyl acetate again, the organic phases were combined, and dried , and concentrated to obtain 195.7 g of compound IIIc with a yield of 83%.

[0042] (2) Preparation of compound IIc:

[0043]

[0044] Compound N-Boc-piperazine (149.1g, 0.8mol) was added to toluene (1700ml), then sodium tert-butoxide (76.8g, 0.8mol) was added, stirred for 40 minutes, and compound IIIc (188.8g, 0.8 mol), the mixture was heated to reflux and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a preparation method of a teneligliptin key intermediate 1-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazine (compound I), and belongs to the technical field of medicine preparation. According to the method of the present invention, a compound IV is adopted as a raw material, and reacts with iodobenzene to obtain a compound III, the compound III reacts with N-Boc-piperazine to obtain a compound II, and the compound II reacts with a suitable acid to remove the Boc protection to obtain the compound I.

Description

technical field [0001] The invention relates to the technical field of pharmaceutical manufacturing, in particular to a method for preparing a key intermediate of tiagliptin. Background technique [0002] 1-(3-Methyl-1-phenyl-1H-pyrazol-5-yl))piperazine is widely used in medicinal chemistry and organic synthesis, especially as an important intermediate of tiagliptin. The chemical name of tiagliptin is 3-[[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-1-piperazinyl]- 2-Pyrrolidinyl]formyl]thiazolidine, whose trade name is Tenelia, is jointly researched and developed by Mitsubishi Tanabe and Daiichi-Sankyo. Tiagliptin was approved for marketing in Japan in September 2011 and is clinically used for the treatment of type 2 diabetes. [0003] 1-(3-Methyl-1-phenyl-1H-pyrazol-5-yl))piperazine mainly has the following methods [0004] The patent W02002 / 014271 of the original research company Mitsubishi Pharmaceuticals announced a preparation method (Scheme 1) of 1-(3-methyl-1-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D231/38
CPCC07D231/38
Inventor 陈芳军李书耘
Owner 湖南华腾制药有限公司